# Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

> **NCT04068597** · PHASE1,PHASE2 · RECRUITING · sponsor: **CellCentric Ltd.** · enrollment: 250 (estimated)

## Conditions studied

- Haematological Malignancy
- Acute Myeloid Leukemia
- Non Hodgkin Lymphoma
- Multiple Myeloma
- Higher-risk Myelodysplastic Syndrome
- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** CCS1477
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Bortezomib
- **DRUG:** Ixazomib
- **DRUG:** Elranatamab
- **DRUG:** Teclistamab
- **DRUG:** Lenalidomide
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04068597
- **Lead sponsor:** CellCentric Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-09
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068597, "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04068597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*